Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for SMO Clinplus Co's Pretax Margin % or its related term are showing as below:
SZSE:301257'
s Pretax Margin % Range Over the Past 10 Years
Min: 8.63 Med: 15.16 Max: 21.19
Current: 8.63
SZSE:301257's Pretax Margin % is ranked better than 70.65% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.37
vs SZSE:301257: 8.63
SMO Clinplus Co (SZSE:301257) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
SMO Clinplus Co Pretax Margin % Related Terms
SMO Clinplus Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for SMO Clinplus Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301257 vs TMO, DHR, NTRA: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, SMO Clinplus Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMO Clinplus Co Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where SMO Clinplus Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMO Clinplus Co (SZSE:301257) has a Pretax Margin % of -4.61% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SMO Clinplus Co and its competitors. Over the past decade, SMO Clinplus Co's Pretax Margin % has ranged from 8.63 to 21.19. According to the industry distribution chart, SMO Clinplus Co ranks #59 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 29.4%.
Is SMO Clinplus Co's Pretax Margin % too high?
SMO Clinplus Co's current Pretax Margin % is -4.61%. Over the past 10 years, this metric has ranged from a low of 8.63 to a high of 21.19. Based on the distribution chart, SMO Clinplus Co ranks #59 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SMO Clinplus Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SMO Clinplus Co's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SMO Clinplus Co ranks #59 out of 201 companies for Pretax Margin %. This puts SMO Clinplus Co in the upper half of its industry. Historically, SMO Clinplus Co's own Pretax Margin % has ranged from 8.63 to 21.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SMO Clinplus Co and its competitors. SMO Clinplus Co's current Pretax Margin % is -4.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMO Clinplus Co stock overvalued right now?
Based on GuruFocus' analysis, SMO Clinplus Co (SZSE:301257) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.90, compared to a current price of ¥37.31 — trading 4.1% below its estimated fair value. The current Pretax Margin % is -4.61%. SMO Clinplus Co's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For SMO Clinplus Co (SZSE:301257), the current Pretax Margin % is -4.61% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMO Clinplus Co (SZSE:301257) Overvalued in 2026?
Based on GuruFocus' analysis, SMO Clinplus Co stock appears to be undervalued.
The current stock price of ¥37.31 is trading 4.1% below its estimated GF Value™ of ¥38.90.
GuruFocus considers SMO Clinplus Co to be Fairly Valued.
Key valuation signals for SZSE:301257:
Pretax Margin %: -4.61%
GF Value™: ¥38.90 vs. price of ¥37.31 (4.1% below fair value)
No single metric tells the full story. See the SZSE:301257 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies, and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
91GF Score
Get the complete analysis for SZSE:301257
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301257 has been successfully added to your 
